FindTrial
Sign In

Delgocitinib

DRUG10 trials

Sponsors

LEO Pharma, Icahn School of Medicine at Mount Sinai, Maryanne Makredes Senna, Aarhus University Hospital

Conditions

Atopic DermatitisCentral Centrifugal Cicatricial AlopeciaChronic Hand EczemaCutaneous T-cell LymphomaFrontal Fibrosing AlopeciaLichen PlanopilarisLichen SclerosusMycosis Fungoides

Phase 1

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
CompletedNCT03826901
LEO PharmaAtopic Dermatitis
Start: 2019-02-20End: 2021-10-29Updated: 2025-02-24
Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema
CompletedNCT05486117
LEO PharmaChronic Hand Eczema
Start: 2022-09-06End: 2022-11-22Updated: 2025-04-04

Phase 2

Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris
RecruitingNCT07487948
Icahn School of Medicine at Mount SinaiCentral Centrifugal Cicatricial Alopecia, Lichen Planopilaris
Start: 2026-05-19End: 2027-12-31Target: 30Updated: 2026-07-10
Trial of Delgocitinib 20 mg/g Cream in Subjects With Frontal Fibrosing Alopecia (FFA)
Not yet recruitingNCT07671157
Maryanne Makredes SennaFrontal Fibrosing Alopecia
Start: 2026-09-10End: 2027-10-10Target: 30Updated: 2026-08-26
Topical JAK-Inhibition of Early-Stage CTCL
Not yet recruitingNCT07781449
Aarhus University HospitalCutaneous T-cell Lymphoma, Mycosis Fungoides
Start: 2026-09-01End: 2030-06-01Target: 15Updated: 2026-08-26

Phase 3

Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials
CompletedNCT04949841
LEO PharmaChronic Hand Eczema
Start: 2021-08-23End: 2023-09-18Updated: 2025-04-08
A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema
CompletedNCT05259722
LEO PharmaChronic Hand Eczema
Start: 2022-06-15End: 2023-12-05Updated: 2025-05-09
Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema
CompletedNCT05355818
LEO PharmaChronic Hand Eczema
Start: 2022-07-14End: 2024-12-17Updated: 2026-08-21
A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema
CompletedNCT06004050
LEO PharmaChronic Hand Eczema
Start: 2023-09-05End: 2025-09-12Updated: 2025-09-25
A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus
RecruitingNCT07335588
LEO PharmaLichen Sclerosus
Start: 2026-05-01End: 2028-12-29Target: 652Updated: 2026-08-07

Related Papers

Minimal Systemic Exposure with Maximal Delgocitinib Cream Use in Patients with Severe Chronic Hand Eczema in the DELTA 2 Randomized, Vehicle-Controlled, Double-Blind, Phase 3 Trial
Dermatology and Therapy2026-05-17
Editorial: Exploring innovative therapies for rare inflammatory skin diseases
Frontiers in Medicine2026-03-19
Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema
Journal of the European Academy of Dermatology and Venereology2025-06-179 citations
Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial.
2025-04-169 citations
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials.
2025-03-1110 citations
655 - Long-term safety and efficacy of delgocitinib cream for up to 36 weeks in adults with chronic hand eczema: results of the phase 3 open-label extension DELTA-3 trial
British Journal of Dermatology2024-08-015 citations